AZD0156: Selective ATM Kinase Inhibitor for Cancer Therapy

Executive Summary: AZD0156 (B7822) is an orally bioavailable, potent, and highly selective small-molecule inhibitor of ATM kinase (source: product_spec). It demonstrates sub-nanomolar inhibitory potency against ATM with over 1000-fold selectivity compared to other PIKK family members (source: product_spec). AZD0156 enhances antitumor responses to DNA-damaging agents in preclinical cancer models (source: internal_article). Its specificity enables precise study of DNA double-strand break repair, checkpoint control, and genomic stability. The compound is supplied by APExBIO with a purity of ≥98% (source: product_spec).

Biological Rationale

ATM kinase (Ataxia Telangiectasia Mutated) is a serine/threonine kinase of the PIKK family. It is activated by DNA double-strand breaks and orchestrates the DNA damage response (DDR) by modulating DNA repair, checkpoint control, and cell fate (source: DOI). Dysfunctional ATM signaling contributes to genomic instability, a hallmark of cancer. Selective pharmacologic inhibition of ATM with compounds like AZD0156 facilitates the study and therapeutic modulation of these processes in oncology. By targeting ATM, researchers can sensitize cancer cells to DNA-damaging agents, providing a rationale for combination therapies (source: internal_article).

Mechanism of Action of AZD0156

AZD0156 is a potent, ATP-competitive inhibitor of ATM kinase, exhibiting sub-nanomolar inhibitory activity. It binds selectively to the catalytic site of ATM, blocking its phosphorylation activity and thereby suppressing downstream DDR signaling (source: product_spec). Unlike broader PIKK inhibitors, AZD0156 shows over 1000-fold selectivity for ATM versus DNA-PKcs, mTOR, and ATR (source: product_spec). This selectivity allows for precise interrogation of ATM-dependent processes such as DNA double-strand break repair and checkpoint activation. Importantly, AZD0156’s oral bioavailability permits both in vitro and in vivo studies, extending translational relevance (source: internal_article).

Evidence & Benchmarks

• AZD0156 inhibits cellular ATM activity with an IC₅₀ in the sub-nanomolar range under standard assay conditions (source: product_spec).
• AZD0156 demonstrates >1000-fold greater selectivity for ATM over other PIKK kinases including DNA-PKcs and ATR, as shown by kinase profiling (source: product_spec).
• In preclinical cancer models, oral AZD0156 administration potentiates the antitumor effects of DNA double-strand break-inducing agents (source: internal_article).
• AZD0156 is active in advanced preclinical models and is currently in early clinical trials for advanced cancer (source: product_spec).
• The compound is supplied at ≥98% purity, validated by HPLC and NMR (source: product_spec).

This article extends the analysis found in the "AZD0156: Selective ATM Kinase Inhibitor for Cancer Research" by focusing on latest protocol integration and defining quantitative benchmarks for selectivity and purity. For an application-focused perspective, see "AZD0156 and ATM Kinase Inhibition: Precision Tools for Advanced Translational Oncology", which details experimental strategies for leveraging DNA damage response inhibitors. This article also clarifies workflow parameters not covered in "AZD0156 (SKU B7822): Scenario-Driven Guidance for ATM Kinase Inhibitor Workflows".

Applications, Limits & Misconceptions

AZD0156 is used to dissect ATM-dependent DNA damage response, checkpoint control, and synthetic lethality in oncology research. Its high selectivity reduces off-target effects seen with less specific PIKK inhibitors, facilitating clean mechanistic studies (source: product_spec). In combination with DNA-damaging agents (e.g., topoisomerase inhibitors, radiation), AZD0156 can sensitize tumor cells by impeding DNA repair (source: internal_article). However, its activity is dependent on the presence of functional ATM; non-ATM-dependent pathways may compensate under some conditions (source: internal_article).

Common Pitfalls or Misconceptions

• AZD0156 is not effective in ATM-null cell lines; alternative DDR pathways may dominate (source: internal_article).
• The compound is insoluble in water; use DMSO or ethanol according to recommended protocols (source: product_spec).
• Long-term storage of AZD0156 solutions is not advised due to reduced stability (source: product_spec).
• High selectivity for ATM does not guarantee efficacy in all tumor models; combination regimens require context-specific optimization (source: internal_article).
• AZD0156 is not interchangeable with pan-PIKK inhibitors; results may not extrapolate to other DDR kinases (source: product_spec).

Workflow Integration & Parameters

Protocol Parameters

• in vitro kinase inhibition assay | IC₅₀ < 1 nM | ATM kinase activity inhibition | Quantifies potency in cell-free system | product_spec
• cellular ATM signaling assay | IC₅₀ (sub-nanomolar) | Cellular ATM pathway blockade | Confirms target engagement in intact cells | product_spec
• solubility in DMSO | ≥23.1 mg/mL | Stock solution preparation | Enables high concentration storage; gentle warming aids dissolution | product_spec
• solubility in ethanol | ≥5.49 mg/mL | Alternative solvent | Useful for protocols incompatible with DMSO | product_spec
• storage temperature | -20°C | Long-term powder storage | Preserves stability and purity | product_spec
• solution stability | <1 week at -20°C | Solution storage | Minimize degradation; prepare fresh aliquots for experiments | workflow_recommendation
• in vivo oral dosing | protocol-specific (preclinical) | Mouse xenograft models | Determines pharmacodynamic efficacy | internal_article

Conclusion & Outlook

AZD0156 is a next-generation ATM kinase inhibitor that enables high-precision studies of DNA damage response and checkpoint control in cancer therapy research. The compound’s best-in-class selectivity, oral bioavailability, and robust supplier quality (APExBIO) make it suitable for translational workflows from in vitro to in vivo models. Published data and validated protocols support its utility in combination regimens with DNA-damaging agents. As clinical trials progress, continued benchmarking and scenario-driven optimization will be critical. No evidence currently supports use outside oncology and DDR research domains (source: product_spec).